
    
      Study Population: Patients with moderate to severe chronic obstructive lung disease.

      Trial Phase: IV

      Study Design: Prospective, randomised, double-blind, placebo- controlled clinical trial.

      Study Medicine: Azithromycin.

      Drug Administration: Oral.

      Drug Dose: 500 mg once daily for 3 days every month.

      Duration of Treatment: 3 years

      Number of Evaluable Patients: 200 per treatment arm

      Number of Included Patients: 400 per treatment arm, 800 patients in total.
    
  